Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

被引：3

作者：

Sznol, M. ^{[1
]}

Ferrucci, P. F. ^{[2
]}

Hogg, D. ^{[3
]}

Atkins, M. ^{[4
]}

Wolter, P. ^{[5
]}

Guidoboni, M. ^{[6
]}

Lebbe, C. ^{[7
]}

Kirkwood, J. ^{[8
]}

Schachter, J. ^{[9
]}

Daniels, G. ^{[10
]}

Hassel, J. ^{[11
]}

Cebon, J. ^{[12
]}

Gerritsen, W. ^{[13
]}

Atkinson, V. ^{[14
,15
]}

Thomas, L. ^{[16
]}

McCaffrey, J. ^{[17
]}

Power, D. ^{[18
]}

Jiang, J. ^{[19
]}

Hodi, F. S. ^{[20
]}

Wolchok, J. ^{[21
]}

机构：

[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA

[2] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy

[3] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[4] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA

[5] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium

[6] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy

[7] Hop St Louis, Dermatol, Paris, France

[8] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA

[9] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel

[10] Moores UCSD Canc Ctr, Med, La Jolla, CA USA

[11] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany

[12] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia

[13] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands

[14] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia

[15] Princess Alexandra Hosp, Greenslopes, Australia

[16] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France

[17] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland

[18] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland

[19] BMS, Oncol, Princeton, NJ USA

[20] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA

[21] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1123P

引用

页数：1

共 50 条

[31] PD-L1 EXPRESSION AS A BIOMARKER FOR NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) AND NIVO ALONE IN ADVANCED MELANOMA (MEL): A POOLED ANALYSIS [J].

Long, Georgina ;

Larkin, James ;

Ascierto, Paolo ;

Hodi, Stephen ;

Rutkowski, Piotr ;

Chiarion-Selini, Vanna ;

Hassel, Jessica ;

Lebbe, Celeste ;

Pavlick, Anna ;

Wagstaff, John ;

Schadendorf, Dirk ;

Dummer, Reinhard ;

Hogg, David ;

Haanen, John ;

Corrie, Pippa ;

Hoeller, Christopher ;

Horak, Christine ;

Wolchok, Jedd ;

Robert, Caroline .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 :126-126

[32] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067) [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J. -J. ;

Cowey, C. L. ;

Lao, C. D. ;

Wagstaff, J. ;

Hogg, D. ;

Hill, A. ;

Carlino, M. S. ;

Wolter, P. ;

Lebbe, C. ;

Schachter, J. ;

Thomas, L. ;

Hassel, J. C. ;

Lorigan, P. ;

Walker, D. ;

Jiang, J. ;

Hodi, F. S. ;

Wolchok, J. D. .

ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 :40-40

[33] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA [J].

Quon, P. ;

Xiao, Y. ;

Sorensen, S. ;

Schultz, M. ;

Monfared, Tahami A. A. .

VALUE IN HEALTH, 2017, 20 (09) :A441-A442

[34] TWO-YEAR OVERALL SURVIVAL (OS) RATES FROM A RANDOMIZED PHASE 2 TRIAL EVALUATING THE COMBINATION OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) VERSUS IPI IN PATIENTS WITH ADVANCED MELANOMA (MEL) [J].

Postow, Michael A. ;

Chesney, Jason ;

Pavlick, Anna C. ;

Robert, Caroline ;

Grossmann, Kenneth ;

McDermott, David ;

Linette, Gerald ;

Meyer, Nicolas ;

Giguere, Jeffrey ;

Agarwala, Sanjiv S. ;

Shaheen, Montaser ;

Ernstoff, Marc S. ;

Minor, David R. ;

Salama, April ;

Taylor, Matthew H. ;

Ott, Patrick A. ;

Jiang, Joel ;

Horak, Christine ;

Wolchok, Jedd D. ;

Hodi, Stephen .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 :130-131

[35] Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). [J].

Weber, Jeffrey S. ;

Gibney, Geoffrey Thomas ;

Sullivan, Ryan J. ;

Sosman, Jeffrey Alan ;

Slingluff, Craig L. ;

Lawrence, Donald P. ;

Logan, Theodore F. ;

Schuchter, Lynn Mara ;

Nair, Suresh ;

Buchbinder, Elizabeth Iannotti ;

Berghorn, Elmer ;

Jiang, Joel ;

Horak, Christine E. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[36] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204) [J].

Tawbi, Hussein ;

Forsyth, Peter ;

Hodi, F. Stephen ;

Lao, Christopher ;

Moschos, Stergios ;

Hamid, Omid ;

Atkins, Michael B. ;

Lewis, Karl ;

Thomas, Reena P. ;

Glaspy, John A. ;

Jang, Sekwon ;

Algazi, Alain ;

Khushalani, Nikhil I. ;

Postow, Michael A. ;

Pavlick, Anna C. ;

Ernstoff, Marc ;

Reardon, David A. ;

Balogh, Agnes ;

Rizzo, Jasmine ;

Margolin, Kim .

BRITISH JOURNAL OF CANCER, 2019, 121 :20-20

[37] A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. [J].

Margolin, Kim Allyson ;

Tawbi, Hussein Abdul-Hassan ;

Ernstoff, Marc S. ;

Hodi, F. Stephen ;

McDermott, David F. ;

Edwards, Robin ;

Avila, Alexandre ;

Atkins, Michael B. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[38] A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI). [J].

Schadendorf, Dirk ;

Ascierto, Paolo Antonio ;

Espinosa, Enrique ;

Haanen, John B. A. G. ;

Hermann, Frank ;

Nathan, Paul D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[39] Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). [J].

Weber, Jeffrey S. ;

Larkin, James M. G. ;

Schadendorf, Dirk ;

Wolchok, Jedd D. ;

Wagstaff, John ;

Dummer, Reinhard ;

Hogg, David ;

Guidoboni, Massimo ;

Sosman, Jeffrey Alan ;

Chmielowski, Bartosz ;

Gerritsen, Winald ;

Bhore, Rafia ;

Walker, Dana ;

Gonzalez, Rene .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[40] Efficacy of nivolumab and ipilimumab (Nivo plus Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP). [J].

Shoushtari, Alexander Noor ;

Navid-Azarbaijani, Pedram ;

Friedman, Claire Frances ;

Panageas, Katherine ;

Postow, Michael Andrew ;

Callahan, Margaret K. ;

Momtaz, Parisa ;

Campbell, Shonnette C. ;

Shames, Yelena ;

Prempeh-Keteku, Nana A. ;

Nwaedozie, Kasiemobi ;

Wolchok, Jedd D. ;

Chapman, Paul B. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →